General Information:

Id: 3,794 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Rattus norvegicus
male
Zucker fatty (fa/fa) and lean (fa/+) rats
article
Reference: Hsiao G et al.(2011) Multi-tissue, selective PPARgamma modulation of insulin sensitivity and metabolic pathways in obese rats Am. J. Physiol. Endocrinol. Metab. 300: E164-E174 [PMID: 20959535]

Interaction Information:

Comment Srebf1 expression in PPARgamma ligand-treated fatty rats was normalized down to lean control (LC) levels and was not different between the ligand treatment groups. Expression of several Srebf1 target genes associated with lipogenesis was also decreased by at least one of the ligand treatments (Elovl5, Fasn, G6pdx, Me1, Scd1). Of these, G6pdx expression was completely normalized to LC levels. Ligand treatment increased pyruvate dehydrogenase kinase-4 (Pdk4) expression. In its active state, PDK4 protein inhibits pyruvate dehydrogenase complex conversion of pyruvate into acetyl-CoA, effectively preventing the accumulation of the fatty acid precursors. Blunted cholesterol synthesis gene expression in FC rats was increased by PPARgamma ligand treatment (Cyp51, Idi1, Sc4mol, Sqle) with Cyp51, Sc4mol, and Sqle expression normalized to LC levels.
Formal Description
Interaction-ID: 37619

drug/chemical compound

Thiazolidinedione

decreases_expression of

gene/protein

ELOVL5

in liver; in obese Zucker rats